- Home
- ANNX vs MPB Comparison
ANNX vs MPB Comparison
Compare ANNX & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- MPB
- Stock Information
- Founded
- ANNX 2011
- MPB 1868
- Country
- ANNX United States
- MPB United States
- Employees
- ANNX N/A
- MPB N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- MPB Major Banks
- Sector
- ANNX Health Care
- MPB Finance
- Exchange
- ANNX Nasdaq
- MPB Nasdaq
- Market Cap
- ANNX 553.2M
- MPB 525.0M
- IPO Year
- ANNX 2020
- MPB N/A
- Fundamental
- Price
- ANNX $4.20
- MPB $29.02
- Analyst Decision
- ANNX Strong Buy
- MPB Buy
- Analyst Count
- ANNX 7
- MPB 2
- Target Price
- ANNX $15.80
- MPB $36.00
- AVG Volume (30 Days)
- ANNX 1.5M
- MPB 71.7K
- Earning Date
- ANNX 11-14-2024
- MPB 01-28-2025
- Dividend Yield
- ANNX N/A
- MPB 2.76%
- EPS Growth
- ANNX N/A
- MPB 14.41
- EPS
- ANNX N/A
- MPB 2.91
- Revenue
- ANNX N/A
- MPB $173,416,000.00
- Revenue This Year
- ANNX N/A
- MPB N/A
- Revenue Next Year
- ANNX N/A
- MPB $19.26
- P/E Ratio
- ANNX N/A
- MPB $9.98
- Revenue Growth
- ANNX N/A
- MPB 4.93
- 52 Week Low
- ANNX $3.86
- MPB $19.20
- 52 Week High
- ANNX $8.40
- MPB $33.87
- Technical
- Relative Strength Index (RSI)
- ANNX 31.21
- MPB 47.74
- Support Level
- ANNX $4.53
- MPB $28.48
- Resistance Level
- ANNX $4.99
- MPB $29.25
- Average True Range (ATR)
- ANNX 0.31
- MPB 0.72
- MACD
- ANNX -0.08
- MPB 0.16
- Stochastic Oscillator
- ANNX 14.07
- MPB 80.62
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.